---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-316819"
form_type: "8-K"
ticker: "NMRA"
cik: "0001885522"
company_name: "Neumora Therapeutics, Inc."
filed_at: "2026-07-27T11:07:30+00:00"
generated_at: "2026-07-27T11:10:11.735549+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Neumora Therapeutics reports favorable NMRA-215 toxicology results, plans IND in Q4 2026

## Summary
- Repeat 13-week rat toxicology study (162 animals) showed no unexpected adverse findings, resolving prior concerns from a study with 5 of 142 animals affected.
- Company plans to submit IND for NMRA-215, an oral NLRP3 inhibitor for obesity and cardiometabolic disease, in Q4 2026 and start Phase 1 by end of 2026.
- NMRA-215 demonstrated class-leading weight loss in diet-induced obesity mouse model, including additive effects with semaglutide and potential for switch/maintenance.
- For-cause audit of prior study revealed discrepancies; company believes prior adverse findings were not drug-related.

## SEC filing metadata
- accession: 0001193125-26-316819
- form_type: 8-K
- ticker: NMRA
- cik: 0001885522
- company_name: Neumora Therapeutics, Inc.
- filed_at: 2026-07-27T11:07:30+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1885522/000119312526316819/0001193125-26-316819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1885522/000119312526316819/nmra-20260727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-316819
- JSON: https://secwatch.observer/filing/0001193125-26-316819.json
- Plain text: https://secwatch.observer/filing/0001193125-26-316819.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.